Osteoporosis Drugs Market in BRIC Nations 2015-2019

BRIC(ブラジル、ロシア、インド、中国)の骨粗鬆症治療薬市場

◆タイトル:Osteoporosis Drugs Market in BRIC Nations 2015-2019
◆商品コード:IRTNTR7210
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年9月16日
◆ページ数:68
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:BRIC(ブラジル、ロシア、インド、中国)
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、BRIC(ブラジル、ロシア、インド、中国)の骨粗鬆症治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、BRIC(ブラジル、ロシア、インド、中国)の骨粗鬆症治療薬市場規模及び予測、治療クラス別分析、市場シェア、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About osteoporosis
Osteoporosis, or porous bone, is a disease characterised by low bone density and structural deterioration of bone tissue, leading to fragile bones. This increases the risk of fractures. Osteoporosis mainly affects women, but can also affect men. In women, bone loss occurs very rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement occurs too slowly. Risk factors for osteoporosis that cannot be controlled include gender, age, body size (low body weight), ethnicity, and family history. Risk factors that can be controlled include sex hormones, medication use, calcium and vitamin intake, alcohol intake, and smoking.

Technavio’s analysts forecast the osteoporosis drugs market in BRIC nations to grow at a CAGR of 17.43% over the period 2014-2019.

[Covered in this report]
This report covers the present scenario and the growth prospects of the osteoporosis drugs market in BRIC nations for the period 2015–2019. To calculate the market size, the report considers revenue generated from the sales of various pharmaceutical products used in the treatment of osteoporosis. Pharmaceutical products are classified as branded and generic drugs.

Technavio’s report, Osteoporosis Drugs Market in BRIC Nations 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Brazil, Russia, India, and China; it also covers the landscape of the osteoporosis drugs market in BRIC nations and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

[Key countries]
• Brazil
• China
• India
• Russia

[Key vendors]
• Amgen
• Eli Lilly
• Merck
• Novartis

[Other prominent vendors]
• Abiogen Pharma
• Deltanoid Pharmaceuticals
• F. Hoffmann La Roche
• GlaxoSmithKline
• IMMD
• Ligand Pharmaceuticals
• Pantarhei Bioscience
• Pfizer
• PhytoHealth
• Radius Health
• UPSHER-SMITH LABORATORIES
• Zosano Pharma

[Market driver]
• Increase in aging population
• For a full, detailed list, view our report

[Market challenge]
• Multiple patent expiries
• For a full, detailed list, view our report

[Market trend]
• Shift toward anabolic treatments
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Osteoporosis: An overview
Understanding osteoporosis
Epidemiology and demography
Risk factors
Symptoms
Diagnosis
Treatment

PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 07: Pipeline Assessment
Key information of pipeline candidates

PART 08: Market segmentation by therapeutic class
Antiresorptive medication
Anabolic medication

PART 09: Market segmentation by line of therapy

PART 10: Geographical segmentation

PART 11: Country overview
China
India
Russia
Brazil

PART 12: Market drivers
Rise in aging population
Emergence of novel agents
High unmet medical needs
Increased incidence of osteoporosis

PART 13: Impact of drivers

PART 14: Market challenges
Expiry of patents
Limited access to diagnostic tools
Poor patient compliance
Inadequate reimbursement policies
Lack of public awareness

PART 15: Impact of drivers and challenges

PART 16: Market trends
Shift toward anabolic treatment
Use of combination therapies
Increased awareness of bone health education

PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 18: Key vendor analysis
Amgen
Eli Lilly
Merck
Novartis

PART 19: Appendix
List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Incidence of osteoporosis-related hip fractures 2012
Exhibit 03: Interpretation of BMD results
Exhibit 04: Osteoporosis drugs market in BRIC 2014-2019 ($ billions)
Exhibit 05: Five forces analysis
Exhibit 06: Product pipeline
Exhibit 07: Segmentation of osteoporosis drugs market in BRIC by therapeutic class
Exhibit 08: Segmentation of osteoporosis drugs market in BRIC by line of therapy
Exhibit 09: Segmentation of osteoporosis drugs market in BRIC by geography 2014
Exhibit 10: Key countries
Exhibit 11: Life expectancy in China (age in years)
Exhibit 12: Population projection of China (millions)
Exhibit 13: Percentage of urban and rural population in China 2013
Exhibit 14: Life expectancy in India (age in years)
Exhibit 15: Population projection of India (millions)
Exhibit 16: Percentage of urban and rural population in India 2013
Exhibit 17: Population projection of people aged 50 and above in Russia 2011 and 2050 (millions)
Exhibit 18: Population projection of Brazil 2011 and 2050 (millions)
Exhibit 19: Life expectancy in Brazil 2010 and 2050 (age in years)
Exhibit 20: Estimated population aged 60 and above in BRIC countries 2010-2013
Exhibit 21: Impact of drivers
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Eli Lilly: YoY growth and revenue of Evista 2010-2014 ($ millions)
Exhibit 24: Eli Lilly: YoY growth and revenue of Forteo 2010-2014 ($ millions)
Exhibit 25: Amgen: YoY growth and revenue of Prolia 2010-2014 ($ millions)
Exhibit 26: Merck: YoY growth and revenue of Fosamax 2011-2014 ($ millions)
Exhibit 27: Novartis: YoY growth and revenue of Reclast/Aclasta 2010-2013 ($ millions)
Exhibit 28: Amgen: Business segmentation by revenue 2014
Exhibit 29: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 30: Amgen: Geographical segmentation by revenue 2014
Exhibit 31: Business segmentation by revenue 2014



【掲載企業】

Amgen, Eli Lilly, Merck, Novartis, Abiogen Pharma, Deltanoid Pharmaceuticals, F. Hoffmann-La Roche, GlaxoSmithKline, IMMD, Ligand Pharmaceuticals, Pantarhei Bioscience, Pfizer, PhytoHealth, Radius Health, Upsher-Smith Laboratories, Zosano Pharma

【資料のキーワード】

骨粗鬆症、骨粗鬆症治療薬、医薬品、ブラジル、ロシア、インド、中国

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[BRIC(ブラジル、ロシア、インド、中国)の骨粗鬆症治療薬市場] (Osteoporosis Drugs Market in BRIC Nations 2015-2019 / IRTNTR7210)販売に関する免責事項
[BRIC(ブラジル、ロシア、インド、中国)の骨粗鬆症治療薬市場] (Osteoporosis Drugs Market in BRIC Nations 2015-2019 / IRTNTR7210)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆